Viridian officer plans $348K stock sale in 2026

Viridian Therapeutics, Inc. (VRDN) is the issuer of common stock that an officer, Jennifer Tousignant, has notified an intention to sell under Rule 144.

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. (VRDN) is the issuer of common stock that an officer, Jennifer Tousignant, has notified an intention to sell under Rule 144. The notice covers 14,212 shares of common stock, with an aggregate market value of $348,194.00, and lists 113,292,269 shares outstanding. The planned sales, through Fidelity Brokerage Services LLC on NASDAQ around August 19, 2026, are sourced from restricted stock vesting, an ESPP purchase, and a stock option exercise.

Key Figures

Shares to be sold: 14,212 shares Aggregate market value: $348,194.00 Shares outstanding: 113,292,269 shares +4 more

7 metrics

Shares to be sold 14,212 shares Number of Viridian Therapeutics common shares covered by the Rule 144 notice

Aggregate market value $348,194.00 Market value of the 14,212 shares referenced in the notice

Shares outstanding 113,292,269 shares Viridian Therapeutics common shares outstanding as referenced in the notice

Restricted stock vesting source 3,494 shares Common shares from restricted stock vesting on 03/03/2026

ESPP purchase source 718 shares Common shares from ESPP purchase on 05/18/2026

Stock option exercise source 10,000 shares Common shares from stock option exercise on 08/19/2026

Approximate sale date 08/19/2026 Proposed date for sale of the covered shares on NASDAQ

Key Terms

Rule 144, restricted stock vesting, ESPP Purchase, Stock Option Exercise

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 03/03/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

ESPP Purchase financial

"Common | 05/18/2026 | ESPP Purchase | Issuer"

Stock Option Exercise financial

"Common | 08/19/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Viridian Therapeutics (VRDN)?

The filing indicates an officer, Jennifer Tousignant, has notified an intent to sell 14,212 VRDN common shares under Rule 144 through Fidelity Brokerage Services LLC, providing advance disclosure of potential insider sales.

How many Viridian Therapeutics (VRDN) shares are intended to be sold and at what value?

The notice covers 14,212 shares of Viridian Therapeutics common stock, with an aggregate market value of $348,194.00. This figure reflects the market value used in the Rule 144 notice for the proposed sale.

What is the share count outstanding for Viridian Therapeutics (VRDN) in this notice?

The notice states that 113,292,269 shares of Viridian Therapeutics common stock are outstanding. This number provides context for the size of the 14,212-share proposed sale under Rule 144.

When are the Viridian Therapeutics (VRDN) shares expected to be sold under this Form 144?

The approximate sale date listed is August 19, 2026. The filing identifies NASDAQ as the securities exchange and Fidelity Brokerage Services LLC as the broker for these proposed Rule 144 sales.

What are the sources of the Viridian Therapeutics (VRDN) shares to be sold?

The shares come from restricted stock vesting (3,494 shares on 03/03/2026), an ESPP purchase (718 shares on 05/18/2026), and a stock option exercise (10,000 shares on 08/19/2026), all in Viridian common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 02:31 PM Accepted by SEC EDGAR 08/19/2026 - 02:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002010978
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Viridian Therapeutics, Inc.\DE
SEC File Number	001-36483
Address of Issuer	221 CRESCENT STREET SUITE 103A WALTHAM MASSACHUSETTS 02453
Phone	617.272.4600
Name of Person for Whose Account the Securities are To Be Sold	Tousignant Jennifer
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	14212	348194.00	113292269	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/03/2026	Restricted Stock Vesting	Issuer			3494	03/03/2026	Compensation
Common	05/18/2026	ESPP Purchase	Issuer			718	05/18/2026	Cash
Common	08/19/2026	Stock Option Exercise	Issuer			10000	08/19/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jennifer Tousignant
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)